The consistent association between high CYP19A1 expression and poor survival outcomes in chemotherapy-treated patients aligns with our in vitro findings demonstrating that CYP19A1 influences chemoresistance in CRC cells. This evidence concerns the gene CYP19A1 and colorectal carcinoma.